Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGNNASDAQ:FHTXNASDAQ:LFCRNASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$3.62-0.5%$3.63$2.65▼$11.00$186.02M-0.42129,134 shs70,753 shsFHTXFoghorn Therapeutics$4.87+3.6%$4.39$2.94▼$10.25$261.98M3.05142,913 shs140,647 shsLFCRLifecore Biomedical$7.96-2.0%$6.91$3.68▼$8.63$300.65M0.71228,579 shs113,725 shsTNYATenaya Therapeutics$0.60-1.3%$0.52$0.36▼$4.06$99.42M2.992.70 million shs1.05 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-0.55%+20.53%-5.94%-15.94%-61.40%FHTXFoghorn Therapeutics-2.89%-3.89%+13.53%+39.05%-18.26%LFCRLifecore Biomedical-0.85%+9.88%+22.84%+15.50%+58.28%TNYATenaya Therapeutics+0.26%+9.42%+35.25%+12.35%-80.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENGNenGene2.5844 of 5 stars3.53.00.00.01.12.50.6FHTXFoghorn Therapeutics2.1244 of 5 stars3.60.00.00.03.21.70.6LFCRLifecore Biomedical1.6011 of 5 stars1.32.00.00.03.84.20.6TNYATenaya Therapeutics3.4062 of 5 stars3.52.00.00.02.04.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$23.29543.25% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13148.97% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.000.50% UpsideTNYATenaya Therapeutics 3.00Buy$6.25936.48% UpsideCurrent Analyst Ratings BreakdownLatest TNYA, LFCR, ENGN, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/23/2025FHTXFoghorn TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025FHTXFoghorn TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$9.004/23/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$4.45 per shareN/AFHTXFoghorn Therapeutics$22.60M12.01N/AN/A($0.82) per share-5.94LFCRLifecore Biomedical$128.26M2.30N/AN/A$0.37 per share21.51TNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/AFHTXFoghorn Therapeutics-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-35.90%-551.09%-13.89%8/15/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)Latest TNYA, LFCR, ENGN, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/A4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGeneN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0912.6612.66FHTXFoghorn TherapeuticsN/A3.163.16LFCRLifecore Biomedical66.362.711.59TNYATenaya TherapeuticsN/A6.686.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%FHTXFoghorn Therapeutics61.55%LFCRLifecore Biomedical83.36%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipENGNenGene10.40%FHTXFoghorn Therapeutics7.58%LFCRLifecore Biomedical32.20%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3151.10 million45.79 millionN/AFHTXFoghorn Therapeutics12055.74 million51.52 millionOptionableLFCRLifecore Biomedical69037.03 million25.10 millionOptionableTNYATenaya Therapeutics110162.67 million83.53 millionOptionableTNYA, LFCR, ENGN, and FHTX HeadlinesRecent News About These CompaniesTenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by AnalystsJune 12, 2025 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short InterestJune 2, 2025 | marketbeat.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%May 15, 2025 | aaii.comATenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comWe're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 10, 2025 | finance.yahoo.comTenaya Therapeutics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comTenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%May 2, 2025 | aaii.comAWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%April 30, 2025 | aaii.comAH.C. Wainwright maintains Buy on Tenaya Therapeutics stockApril 26, 2025 | investing.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%April 26, 2025 | aaii.comATenaya announces interim data from ongoing RIDGE studyApril 25, 2025 | markets.businessinsider.comTenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025April 24, 2025 | globenewswire.comTenaya Slashes a Third of Workforce to Fund Development of Cardio Gene TherapiesApril 1, 2025 | biospace.comBWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%April 1, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNYA, LFCR, ENGN, and FHTX Company DescriptionsenGene NASDAQ:ENGN$3.62 -0.02 (-0.55%) Closing price 04:00 PM EasternExtended Trading$3.57 -0.05 (-1.27%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Foghorn Therapeutics NASDAQ:FHTX$4.87 +0.17 (+3.62%) Closing price 04:00 PM EasternExtended Trading$4.87 0.00 (0.00%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$7.96 -0.16 (-1.97%) Closing price 04:00 PM EasternExtended Trading$7.96 +0.00 (+0.06%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Tenaya Therapeutics NASDAQ:TNYA$0.60 -0.01 (-1.34%) Closing price 04:00 PM EasternExtended Trading$0.61 +0.01 (+1.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
